Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Lactobacillus plantarum LPL28 metabolites
- Development stage
- Preclinical
- Lead developer
- Synbio Tech
- Modality
- Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Administration
- Oral
01
Overview
Lactobacillus plantarum LPL28 metabolites are a collection of bioactive compounds, often referred to as postbiotics, produced by the specific probiotic bacterial strain Lactobacillus plantarum LPL28. These metabolites have demonstrated a range of biological activities, including selective cytotoxicity against cancer cells, inhibition of autophagy-related responses, modulation of gut microbiota composition, and improvement of metabolic functions. They also contribute to immune system modulation by influencing cytokine levels and enhancing gut barrier integrity. Furthermore, these metabolites have shown potential in alleviating allergic reactions. Research suggests their utility in both food compositions and potential pharmaceutical applications.
- Other names
- L. plantarum LPL28 metabolitespostbiotic metabolites of Lactobacillus plantarum LPL28
02
Targets
Neuraminidase
Beyond the preview
Go deeper on Lactobacillus plantarum LPL28 metabolites.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Lactobacillus plantarum LPL28 metabolites.